Concourse Financial Group Securities, Inc. Iterum Therapeutics PLC Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share
Q2 2022 Aug 09, 2022	BUY	$0.19 - $0.36 $0 - $0
Q1 2022 May 09, 2022	BUY	$0.31 - $0.45 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$0.39 - $0.74 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$0.54 - $2.29 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$0.97 - $2.39 $0 - $0
Q1 2021 May 13, 2021	BUY	$0.97 - $2.73 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$0.46 - $1.2 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$0.58 - $1.22 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$1.19 - $4.38 $0 - $0
Q1 2020 May 13, 2020	BUY	$1.55 - $4.56 $0 - $0
Q4 2019 Feb 14, 2020	BUY	$1.7 - $5.99 $0 - $0
Q3 2019 Nov 13, 2019	BUY	$5.77 - $7.65 $0 - $0
Q2 2019 Aug 13, 2019	BUY	$6.09 - $9.1 $0 - $0
Q1 2019 May 15, 2019	BUY	$4.88 - $8.17 $0 - $0
Q4 2018 Feb 14, 2019	BUY	$5.01 - $7.9 $0 - $0
Q3 2018 Nov 13, 2018	BUY	$6.24 - $10.4 $0 - $0

Others Institutions Holding ITRM

# of Institutions

Shares Held

Call Options Held

Put Options Held

Blue Bell Private Wealth Management, LLC

66
Shares

$85
0.0% of portfolio

View Full List

About Iterum Therapeutics plc

Ticker ITRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,233,400
Market Cap $15.9M
Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract inf...

More about ITRM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account